针对YES1增强化疗,向治疗和瘤免疫治疗的疗效
Dayong Zheng1, Yiran Wang1, Jun Li2
1School of Pharmacy, North China University of Science and Technology, 21 Bohai Road, Caofeidian District, Tangshan, China.
Cellular signalling
|September 4, 2025
概括
针对山口瘤病毒同源1 (YES1),这是瘤进展和治疗耐药性的关键驱动因素,为癌症治疗提供了一个有前途的策略. 特别是在组合疗法中,YES1 抑制剂具有协同作用的抗瘤作用,并有可能改善患者的治疗结果.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 在固体瘤中,YES1 (山口瘤病毒同类1) 是SRC家族的氨酸激酶.
- 通过绕道途径促进瘤进展,转移和抗癌疗法.
- 现有的SRC类激酶抑制剂由于毒性和缺乏选择性而面临限制.
研究的目的:
- 总结YES1驱动瘤进展和抵抗的机制.
- 审查YES1选择性抑制剂和组合疗法的潜力.
- 讨论针对YES1的新型治疗策略.
主要方法:
- 关于YES1的文献综述和现有研究.
- 分析YES1在致癌途径中的作用 (例如,YES1-YAP1,EGFR-YES1交叉声).
- 探索YES1在瘤微环境中的功能和合成致死性.
主要成果:
- YES1在瘤生物学的多个方面发挥着关键作用,包括生长和转移.
- YES1对治疗耐药性有显著的作用.
- 选择性YES1抑制剂和组合疗法显示出协同作用的抗瘤作用.
结论:
- 针对YES1是克服耐药性和抑制瘤生长的可行策略.
- 涉及YES1抑制剂的组合方法对癌症治疗具有显著的前景.
- 对YES1向治疗的进一步研究可能会改善患者的治疗结果和生活质量.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


